Entero Therapeutics, Inc. (GRDX) — S-1/A Filings
All S-1/A filings from Entero Therapeutics, Inc.. Browse 3 S-1/A reports with AI-powered summaries and risk analysis.
S-1/A Filings (3)
-
Entero Therapeutics Faces Liquidity Crunch, Rescinds ImmunogenX Merger
— Sep 10, 2025 Risk: high
Entero Therapeutics, Inc. (GRDX) is focused on developing Adrulipase for gastrointestinal diseases, having discontinued Latiglutenase, Capeserod, and Niclosamid -
Entero Therapeutics Amends S-1, Signals Continuous Offering
— Jun 23, 2025 Risk: high
Entero Therapeutics, Inc. (GRDX) filed an S-1/A on June 23, 2025, as an amendment to its registration statement, indicating a proposed delayed or continuous off -
Entero Therapeutics Amends S-1/A for Continuous Offering
— Jun 5, 2025 Risk: medium
Entero Therapeutics, Inc. (GRDX) filed an S-1/A on June 5, 2025, as an amendment to its registration statement under the Securities Act of 1933, indicating a pr
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX